La Merie

STUTTGART, Germany I October 22, 2013 I A new report released by La Merie Publishing analyzes the opportunities arising from the use of the T-cell receptor (TCR) in recombinant protein and antibody products as well as in T-cell therapy. The report entitled „The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry“ describes the current state-of-the art of TCR technologies including the monoclonal TCR (mTCR) and single-chain TCR (scTCR) in immunoglobulin and immunocytokine fusion proteins as well as in cytotoxic T-lymphocytes. The unique feature of the T-cell receptor is its ability to target intracellular protein derived peptides presented in the context of the HLA system. This opens up a whole new avenue for targeting in cancer and viral diseases by rendering intracellular antigens so far undruggable to targets accessible for antibodies, proteins and cellular therapies. This approach is becoming validated no only by the first commercial agreements between Big Pharma/Biotech and TCR technology providers, but also by clinical studies with the first TCR-based therapeutics in development.

The report can be found at This investigation summarizes current activities in the TCR field presents upcoming commercial opportunities for the pharmaceutical and biotechnology industry. As a rather new field of reserach and development in the pharma industry, there are still untapped areas for new entrants regarding platform technologies and products for development.

About La Merie Publising

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting services in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal  To read more about La Merie Publising, plrase visit our website

Published in Press Room

October 17, 2013 I Undoubtedly, antibodies are a hot area for biotech and pharma companies. Development of antibody therapeutics not only seems to have a lower attrition rate than that of small molecules (at least for toxicity reasons), but antibody products are extremely commercially successful. No wonder, that many companies are „jumping on the wagon" of antibodies. However, only a fraction of the companies is working on antibody molecules directed against new targets. Many, if not the majority is focused on improving antibodies directed against validated and commercially successful targets or directly developing biosimilar versions. Risk aversion cannot be the only reason, but availability of new targets for antibodies seems to be a major bottleneck for industry.

One reason might be that target discovery so far has been focused on extracellular targets (proteins, carbohydrates, glycolipids), because intracellular targets are „not accessable" for antibodies. However, intracellular tumor-associated proteins make out more than 80% of potential cancer drug targets. One company recently has raised considerable interest when it closed within a short periof of time two significant deals with Big Pharma/Biotech companies for intracellular targets and T-cell receptor (TCR) based therapeutics in the field of cancer and viral diseases. This seems to be a kind of proof-of-concept for the attractiveness of the T-Cell Receptor for biopharmaceutical industry.

In light of the potential breakthrough character of the TCR technology, La Merie Publishing has performed a comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective. The report can be found in our online store at .

Published in Blog